Recent issues in breast cancer detection and the premarket approval by the food and drug administration of a US system for breast lesion evaluation: What happened to science?

被引：9
|
作者：
Kopans, DB
机构：
[1] Department of Radiology, Massachusetts General Hospital, Boston, MA 02114
来源：
RADIOLOGY | 1997年 / 202卷 / 02期
关键词：
breast neoplasms; diagnosis; breast; US; Devil's Advocate; ultrasound; (US); utilization;
D O I：
10.1148/radiology.202.2.9015048
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：315 / 316
页数：2
相关论文
共 24 条
  • [21] CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Bloomquist, Erik
    Sanchez, Jacquelyn
    Wedam, Suparna B.
    Singh, Harpreet
    Amiri-Kordestani, Laleh
    Ibrahim, Amna
    Sridhara, Rajeshwari
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Blumenthal, Gideon M.
    Pazdur, Richard
    Beaver, Julia A.
    Prowell, Tatiana M.
    LANCET ONCOLOGY, 2020, 21 (02): : 250 - 260
  • [22] A US food and drug administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy
    Singh, Harpreet
    Howie, Lynn J.
    Bloomquist, Erik
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Tang, Shengui
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Goldberg, Kirsten
    Mckee, Amy
    Beaver, Julia A.
    Pazdur, Richard
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Prowell, Tatiana M.
    Bloomquist, Erik
    Tang, Shenghui
    Wedam, Suparna B.
    Royce, Melanie
    Krol, Danielle
    Osgood, Christy
    Ison, Gwynn
    Sridhara, Rajeshwari
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    LANCET ONCOLOGY, 2021, 22 (11): : 1573 - 1581
  • [24] Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis (vol 22, pg 1573, 2021)
    Gao, J. J.
    Cheng, J.
    Prowell, T. M.
    LANCET ONCOLOGY, 2021, 22 (11): : E472 - E472
123